Melevodopa
Chemical compound
- N04BA04 (WHO)
- methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
- 7101-51-1
- 23497
- 21968 Y
- M30686U4X4
- D07304 Y
- DTXSID9048433
- Interactive image
- O=C(OC)[C@@H](N)Cc1cc(O)c(O)cc1
InChI
- InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1 Y
- Key:XBBDACCLCFWBSI-ZETCQYMHSA-N Y
Melevodopa (brand name Levomet) is a dopaminergic agent. It is the methyl ester of levodopa. It is used in tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa.[1]
See also
- Etilevodopa
References
- ^ Hickey P, Stacy M (2011). "Available and emerging treatments for Parkinson's disease: a review". Drug Design, Development and Therapy. 5: 241–54. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
- v
- t
- e
DA precursors |
|
---|---|
DA receptor agonists |
|
MAO-B inhibitors | |
COMT inhibitors | |
AAAD inhibitors |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e